Paul Jank M. A.
Research Fellow, Leitung Labore für translationale Forschung
Contact information
+49 6421 58-65818 +49 6421 58-65640 paul.jank@ 1 Baldingerstraße35033 Marburg
Kopfklinik (Room: +3/09410)
Organizational unit
Philipps-Universität Marburg Medizin (Fb20) Interdisziplinäres Medizinisches Zentrum Institut für PathologiePublications
To the publications in the research information systemHead of translational research laboratory
Office hours
- Mon–Fri: 8:00–16:30
Focus
- clinical studies
- research management
- translational medicine
- biomarker validation
Seminars/Workshops
- [webinar] Wie trägt die digitale Mikroskopie
zu Ihrer Forschungsarbeit bei? (How does digital microscopy contribute to your research work?)
- [webinar] Wie trägt die digitale Mikroskopie
Vita
- since 03/2019: [research assistant/science manager] Institute of Pathology, Philipps-Universität Marburg
- 03/2017–02/2019: [research assistant/biotechnician] Institute of Pathology, Charité Universitätsmedizin Berlin
- 04/2016–03/2017: [biological-technical assistant] Institute of Pathology, Charité Universitätsmedizin Berlin
Education/Studies
- 11/2017–12/2021: [Master of Arts] Management im Gesundheitswesen (healthcare management), Hochschule Fresenius
- 10/2012–03/2016: [Bachelor of Science] biotechnology, Beuth Hochschule für Technik, Berlin
- 09/2009–06/2012: [biotechnician and biological-technical assistant] Charité Universitätsmedizin, Berlin
Publications
- Denkert C. & Untch M. & Benz S. & Schneeweiss A. & Weber K. & Schmatloch S. & Jackisch C. & Sinn H. & Golovato J. & Karn T. & Marmé F. & Link T. & Budczies J. & Nekljudova V. & Schmitt W. & Stickeler E. & Müller V. & Jank P. & Parulkar R. & Heinmöller E. & Sanborn J. & Schem C. & Sinn B. & Soon-Shiong P. & van Mackelenbergh M. & Fasching P. & Rabizadeh S. & Loibl S. (2021)
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
in: Annals of Oncology
10.1016/j.annonc.2020.12.016 - Erber R. & Hartmann A. & Fasching P. A. & Ruebner M. & Stöhr R. & Beckmann M. W. & Zentgraf M. & Popp V. & Weidler J. & Simon I. & Becker S. & Huebner H. & Fischer J. & Rocco E. G. & Viale G. & Cayre A. & Penault-Llorca F. & Casas T. C. & Pérez-Miés B. & Palacios J. & Jank P. & Denkert C. & Khoury L. & Mairinger T. & Ferrazzi F. (2021)
Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment
in: Cancers (13)
10.3390/cancers13184718 - Jank P. & Lindner J. L. & Lehmann A. & Pfitzner B. M. & Blohmer J.-U. & Horst D. & Kronenwett R. & Denkert C. & Schmitt W. D. (2021)
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
in: Breast Cancer Research and Treatment
10.1007/s10549-021-06415-0 - Jurmeister P. & Weber K. & Villegas S. & Karn T. & Untch M. & Thieme A. & Müller V. & Taube E. & Fasching P. & Schmitt W. D. & Marmé F. & Stickeler E. & Sinn B. V. & Jank P. & Schem C. & Klauschen F. & van Mackelenbergh M. & Denkert C. & Loibl S. & Capper D. (2021)
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
in: Clinical Epigenetics (13)
10.1186/s13148-021-01176-5 - Konukiewitz B. & Kasajima A. & Schmitt M. & Schwamborn K. & Groll T. & Schicktanz F. & Delbridge C. & Schütze L. M. & Wilhelm D. & Lang C. & Lange S. & Foersch S. & Jank P. & Steiger K. & von Werder A. & Denkert C. & Weichert W. & Klöppel G. & Jesinghaus M. (2021)
Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker?
in: Cancers
10.3390/cancers13205111 - Llop-Guevara A. & Loibl S. & Villacampa G. & Vladimirova V. & Schneeweiss A. & Karn T. & Zahm D.-M. & Herencia-Ropero A. & Jank P. & van Mackelenbergh M. & Fasching P. & Marmé F. & Stickeler E. & Schem C. & Dienstmann R. & Florian S. & Nekljudova V. & Balmaña J. & Hahnen E. & Denkert C. & Serra V. (2021)
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
in: Annals of Oncology (32)
10.1016/j.annonc.2021.09.003 - Wagner B. R. & Adamus A. L. & Sönnecken D. & Vahdad R. & Jank P. & Denkert C. & Mahnken A. H. & Seitz G. (2021)
Establishment of a new valid animal model for the evaluation of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric rhabdomyosarcoma.
in: Pediatric blood & cancer
10.1002/pbc.29202 - Amgad M. & Stovgaard E. S. & Balslev E. & Thagaard J. & Chen W. & Dudgeon S. & Sharma A. & Kerner J. K. & Denkert C. et al. (2020)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.
in: NPJ breast cancer (6)
10.1038/s41523-020-0154-2 - Hudeček J. & Voorwerk L. & van Seijen M. & Nederlof I. & de Maaker M. & van den Berg J. & van de Vijver K. K. & Sikorska K. & Adams S. & Demaria S. & Viale G. & Nielsen T. O. & Badve S. S. & Michiels S. & Symmans W. F. & Sotiriou C. & Rimm D. L. & Hewitt S. M. & Denkert C. & Loibl S. & Loi S. & Bartlett J. M. S. & Pruneri G. & Dillon D. A. & Cheang M. C. U. & Tutt A. & Hall J. A. & Kos Z. & Salgado R. & Kok M. & Horlings H. M. & the International Immuno-Oncology Biomarker Working Group (2020)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
in: NPJ breast cancer (6)
10.1038/s41523-020-0155-1 - Jank P. & Gehlhaar C. & Bianca L. & Caterina F. & Andreas S. & Karn T. & Marmé F. & Sinn H.-P. & van Mackelenbergh M. & Sinn B. & Zahm D.-M. & Ingold-Heppner B. & Schem C. & Stickeler E. & Fasching P. A. & Nekljudova V. & Taube E. T. & Heppner F. & Müller V. & Denkert C. & Loibl S. (2020)
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
in: PloS one (15)
10.1371/journal.pone.0238021 - Karn T. & Denkert C. & Weber K. E. & Holtrich U. & Hanusch C. & Sinn B. V. & Higgs B. W. & Jank P. & Sinn H. P. & Huober J. & Becker C. & Blohmer J.-U. & Marmé F. & Schmitt W. D. & Wu S. & van Mackelenbergh M. & Müller V. & Schem C. & Stickeler E. & Fasching P. A. & Jackisch C. & Untch M. & Schneeweiss A. & Loibl S. (2020)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
in: Annals of Oncology (31)
10.1016/j.annonc.2020.05.015 - Karsten M. M. & Beck M. H. & Rademacher A. & Knabl J. & Blohmer J.-U. & Jückstock J. & Radosa J. C. & Jank P. & Rack B. & Janni W. (2020)
VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment.
in: Scientific reports (10)
10.1038/s41598-020-59823-5 - Kos Z. & Roblin E. & Kim R. S. & Michiels S. & Gallas B. D. & Chen W. & van de Vijver K. K. & Goel S. & Adams S. et al. (2020)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
in: NPJ breast cancer (6)
10.1038/s41523-020-0156-0 - Kulbe H. & Klein O. & Wu Z. & Taube E. T. & Kassuhn W. & Horst D. & Darb-Esfahani S. & Jank P. & Abobaker S. & Ringel F. & du Bois A. & Heitz F. & Sehouli J. & Braicu E. I. (2020)
Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging.
in: Cancers (12)
10.3390/cancers12082000 - Steven A. & Friedrich M. & Jank P. & Heimer N. & Budczies J. & Denkert C. & Seliger B. (2020)
What turns CREB on? And off? And why does it matter?
in: Cellular and molecular life sciences (77)
10.1007/s00018-020-03525-8 - Westhoff C. C. & Jank P. & Jacke C. O. & Albert U.-S. & Ebrahimsade S. & Barth P. J. & Moll R. (2020)
Prognostic relevance of the loss of stromal CD34 positive fibroblasts in invasive lobular carcinoma of the breast.
in: Virchows Archiv (477)
10.1007/s00428-020-02835-3 - Klein O. & Kanter F. & Kulbe H. & Jank P. & Denkert C. & Nebrich G. & Schmitt W. D. & Wu Z. & Kunze C. A. & Sehouli J. & Darb-Esfahani S. & Braicu I. & Lellmann J. & Thiele H. & Taube E. T. (2019)
MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.
in: Proteomics. Clinical applications (13)
10.1002/prca.201700181 - Loibl S. & Treue D. & Budczies J. & Weber K. & Stenzinger A. & Schmitt W. D. & Weichert W. & Jank P. & Furlanetto J. & Klauschen F. & Karn T. & Pfarr N. & von Minckwitz G. & Möbs M. & Jackisch C. & Sers C. & Schneeweiss A. & Fasching P. A. & Schem C. & Hummel M. & van Mackelenbergh M. & Nekljudova V. & Untch M. & Denkert C. (2019)
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
in: Clinical cancer research (25)
10.1158/1078-0432.CCR-18-3258 - Rüder U. & Denkert C. & Kunze C. A. & Jank P. & Lindner J. & Jöhrens K. & Kulbe H. & Sehouli J. & Dietel M. & Braicu E. & Darb-Esfahani S. (2019)
APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.
in: Histology and histopathology (34)
10.14670/HH-18-050 - Sehouli J. & Braicu E. I. & Richter R. & Denkert C. & Jank P. & Jurmeister P. S. & Kunze C. A. & Budczies J. & Darb-Esfahani S. & Schmitt W. D. & Traut A. & Grabowski J. & Taube E. T. & Plett H. (2019)
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
in: Human pathology (85)
10.1016/j.humpath.2018.10.020 - Voglstaetter M. & Thomsen A. R. & Nouvel J. & Koch A. & Jank P. & Navarro E. G. & Gainey-Schleicher T. & Khanduri R. & Groß A. & Rossner F. & Blaue C. & Franz C. M. & Veil M. & Puetz G. & Hippe A. & Dindorf J. & Kashef J. & Thiele W. & Homey B. & Greco C. & Boucheix C. & Baur A. & Erbes T. & Waller C. F. & Follo M. & Hossein G. & Sers C. & Sleeman J. & Nazarenko I. (2019)
Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles.
in: The Journal of pathology (248)
10.1002/path.5281
- Denkert C. & Untch M. & Benz S. & Schneeweiss A. & Weber K. & Schmatloch S. & Jackisch C. & Sinn H. & Golovato J. & Karn T. & Marmé F. & Link T. & Budczies J. & Nekljudova V. & Schmitt W. & Stickeler E. & Müller V. & Jank P. & Parulkar R. & Heinmöller E. & Sanborn J. & Schem C. & Sinn B. & Soon-Shiong P. & van Mackelenbergh M. & Fasching P. & Rabizadeh S. & Loibl S. (2021)
Presentation/Conferences
- 2021: [presentation] What can you expect from the digitization of your research work today?
Hint:
In case of inaccurate personal data, please inform the appropriate Personnel Data Agent.
1 The email addresses are only selectable in the intranet. To complete an email address, merge following string ".uni-marburg.de" or "uni-marburg.de" to the end of the email address.
1 The email addresses are only selectable in the intranet. To complete an email address, merge following string ".uni-marburg.de" or "uni-marburg.de" to the end of the email address.